The price-to-earnings ratio for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is above average at 39.39x, Company’s 36-month beta value is 0.29.Analysts have differing opinions on the stock, with 14 analysts rating it as a “buy,” 8 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BMRN is 188.20M, and currently, short sellers hold a 2.72% ratio of that floaft. The average trading volume of BMRN on November 28, 2024 was 1.77M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BMRN) stock’s latest price update
The stock of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has increased by 0.83 when compared to last closing price of 64.88. Despite this, the company has experienced a 4.57% gain in its stock price over the last five trading sessions. marketbeat.com reported 2024-11-22 that BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%.
BMRN’s Market Performance
Biomarin Pharmaceutical Inc (BMRN) has seen a 4.57% rise in stock performance for the week, with a -6.42% decline in the past month and a -28.40% plunge in the past quarter. The volatility ratio for the week is 1.98%, and the volatility levels for the past 30 days are at 2.28% for BMRN. The simple moving average for the past 20 days is 0.46% for BMRN’s stock, with a -18.85% simple moving average for the past 200 days.
Analysts’ Opinion of BMRN
Many brokerage firms have already submitted their reports for BMRN stocks, with Wolfe Research repeating the rating for BMRN by listing it as a “Outperform.” The predicted price for BMRN in the upcoming period, according to Wolfe Research is $95 based on the research report published on November 15, 2024 of the current year 2024.
Raymond James gave a rating of “Outperform” to BMRN, setting the target price at $79 in the report published on October 10th of the current year.
BMRN Trading at -3.69% from the 50-Day Moving Average
After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.29% of loss for the given period.
Volatility was left at 2.28%, however, over the last 30 days, the volatility rate increased by 1.98%, as shares sank -1.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.04% lower at present.
During the last 5 trading sessions, BMRN rose by +4.57%, which changed the moving average for the period of 200-days by -24.05% in comparison to the 20-day moving average, which settled at $65.12. In addition, Biomarin Pharmaceutical Inc saw -32.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMRN starting from Guyer Charles Greg, who sale 5,278 shares at the price of $66.37 back on Nov 12 ’24. After this action, Guyer Charles Greg now owns 68,909 shares of Biomarin Pharmaceutical Inc, valued at $350,324 using the latest closing price.
Guyer Charles Greg, the Officer of Biomarin Pharmaceutical Inc, proposed sale 5,278 shares at $66.37 during a trade that took place back on Nov 12 ’24, which means that Guyer Charles Greg is holding shares at $350,324 based on the most recent closing price.
Stock Fundamentals for BMRN
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.78 for the gross margin
The net margin for Biomarin Pharmaceutical Inc stands at 0.12. The total capital return value is set at 0.05. Equity return is now at value 6.25, with 4.74 for asset returns.
Based on Biomarin Pharmaceutical Inc (BMRN), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.69. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 19.36.
Currently, EBITDA for the company is 310.28 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 4.51. The receivables turnover for the company is 3.54for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.27.
Conclusion
In a nutshell, Biomarin Pharmaceutical Inc (BMRN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
